MEI Pharma Analyst Ratings
MEI Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 03/25/2022 | 922.76% | BTIG | $11 → $4 | Maintains | Buy |
| 03/25/2022 | 667.07% | Truist Securities | $8 → $3 | Maintains | Buy |
| 03/25/2022 | 1178.45% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/25/2022 | 411.38% | Wells Fargo | $13 → $2 | Downgrades | Overweight → Equal-Weight |
| 03/25/2022 | 411.38% | Stifel | $6 → $2 | Downgrades | Buy → Hold |
| 03/25/2022 | 155.69% | Jefferies | $4 → $1 | Downgrades | Buy → Hold |
| 02/03/2022 | 922.76% | Jefferies | → $4 | Initiates Coverage On | → Buy |
| 05/29/2020 | 3991.03% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/13/2019 | — | BTIG | Initiates Coverage On | → Buy | |
| 12/20/2018 | 2456.89% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/27/2018 | 1689.82% | Stifel | $2.5 → $7 | Upgrades | Hold → Buy |
| 07/13/2018 | 2968.27% | SunTrust Robinson Humphrey | → $12 | Initiates Coverage On | → Buy |
| 06/06/2018 | — | Wells Fargo | Upgrades | Market Perform → Outperform | |
| 04/12/2018 | 1689.82% | Laidlaw & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 12/06/2022 | — | Truist证券 | 评级下调 | 购买→Hold | |
| 03/25/2022 | 922.76% | BTIG | $11 → $4 | 维护 | 买 |
| 03/25/2022 | 667.07% | Truist证券 | $8 → $3 | 维护 | 买 |
| 03/25/2022 | 1178.45% | HC Wainwright公司 | $10 → $5 | 维护 | 买 |
| 03/25/2022 | 411.38% | 富国银行 | $13 → $2 | 评级下调 | 超重→等重 |
| 03/25/2022 | 411.38% | Stifel | $6 → $2 | 评级下调 | 购买→Hold |
| 03/25/2022 | 155.69% | 杰富瑞 | $4 → $1 | 评级下调 | 购买→Hold |
| 02/03/2022 | 922.76% | 杰富瑞 | → $4 | 开始承保 | →购买 |
| 05/29/2020 | 3991.03% | SunTrust Robinson Humphrey | → $16 | 开始承保 | →购买 |
| 02/13/2019 | — | BTIG | 开始承保 | →购买 | |
| 12/20/2018 | 2456.89% | HC Wainwright公司 | → $10 | 开始承保 | →购买 |
| 07/27/2018 | 1689.82% | Stifel | $2.5 → $7 | 升级 | 持有→购买 |
| 07/13/2018 | 2968.27% | SunTrust Robinson Humphrey | → $12 | 开始承保 | →购买 |
| 06/06/2018 | — | 富国银行 | 升级 | 市场表现优于→ | |
| 04/12/2018 | 1689.82% | 莱德劳公司 | → $7 | 开始承保 | →购买 |
What is the target price for MEI Pharma (MEIP)?
美药(MEIP)的目标价是多少？
The latest price target for MEI Pharma (NASDAQ: MEIP) was reported by Truist Securities on December 6, 2022. The analyst firm set a price target for $0.00 expecting MEIP to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
美药(纳斯达克代码：MEIP)的最新目标价是由Truist证券于2022年12月6日报道的。这家分析公司将目标价定为0.00美元，预计中东和中东石油价格将在12个月内下跌(跌幅可能为-100.00%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for MEI Pharma (MEIP)?
美药(Mei Pharma)最近的分析师评级是多少？
The latest analyst rating for MEI Pharma (NASDAQ: MEIP) was provided by Truist Securities, and MEI Pharma downgraded their hold rating.
美药(纳斯达克股票代码：MEIP)的最新分析师评级由Truist Securities提供，美药下调了其持有评级。
When is the next analyst rating going to be posted or updated for MEI Pharma (MEIP)?
美医药(MEIP)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MEI Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MEI Pharma was filed on December 6, 2022 so you should expect the next rating to be made available sometime around December 6, 2023.
分析师在进行了广泛的研究后得出了股票评级，这些研究包括查看公开的财务报表，与美药的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。美医药的上一次评级是在2022年12月6日提交的，因此你应该预计下一次评级将在2023年12月6日左右公布。
Is the Analyst Rating MEI Pharma (MEIP) correct?
分析师对美医药(Mei Pharma)的评级正确吗？
While ratings are subjective and will change, the latest MEI Pharma (MEIP) rating was a downgraded with a price target of $0.00 to $0.00. The current price MEI Pharma (MEIP) is trading at is $0.39, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的美药(MEIP)评级被下调，目标价为0.00美元至0.00美元。美药(Mei Pharma)目前的交易价格为0.39美元，超出了分析师的预测区间。